In a recent study, more than 40% of patients with relapsed or refractory germ cell tumors experienced a clinical benefit with cabozantinib.

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

The ethics of direct-to-consumer ads from pharmaceutical companies is being debated as the FDA looks towards possibly banning them altogether.

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer. To date, no phase 3 trial has demonstrated a ...

Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or ...

Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with MIBC who did not receive radical cystectomy.

Patients who receive durvalumab plus tremelimumab for resected RCC report worse quality of life compared to those who receive active monitoring.

Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...